Insider transactions

Fred B Craves

CIK 1014095 · last filed 2025-03-14

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$163.10M
Companies
5
Total Filings
70
Lifetime Open-Market Net
-$217.80M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MDGL price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
750 BATTERY ST
STE 600
SAN FRANCISCO, CA 94111
Related Filers
MEDAREX INC — 5 joint filings, latest 2005-07-25
INCYTE CORP — 4 joint filings, latest 2005-06-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MDGL Director 352,779 $437.25 $154.25M -$220.59M 26 2025-03-14
TWST Director 58,168 $151.36 $8.80M $0 2 2019-10-09
DERM Director 9,000 $5.09 $45.8K $1.80M 8 2019-06-14
PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Director 635,739 — — $1.00M 21 2011-06-10
VIA Pharmaceuticals, Inc. (VIAP) Delisted Director — — — $0 1 2009-03-16

Recent Filings · Page 7 of 7

70 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2008-01-14 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +12,600 $50.1K EDGAR
2008-01-10 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +20,000 $84.7K EDGAR
2008-01-07 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +11,300 $47.7K EDGAR
2008-01-07 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +20,000 $85.5K EDGAR
2007-08-31 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +5,328 $31.4K EDGAR
2007-08-31 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +352 $2.0K EDGAR
2007-08-16 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +368 $2.0K EDGAR
2007-08-14 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +972 $5.3K EDGAR
2007-06-18 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Grant (A) — $0 EDGAR
2007-04-30 PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Buy (P) +79,498 $503.2K EDGAR
Showing 61–70 of 70
Page 7 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.